At the 40th J.P. Morgan Healthcare Conference, Moderna Inc (NASDAQ:MRNA) said it expects FY21 product sales of approximately $17.5 billion.
- In the Q3 earnings release, the company expected product sales of $15 billion - $18 billion.
- See the related company presentation here.
- In 2021, the company shipped approximately 807 million doses of the Moderna COVID-19 vaccine. About 25% of all doses delivered in 2021 went to low- and middle-income countries through direct sales by Moderna and donations from high-income countries.
- Moderna has signed 2022 Advanced Purchase Agreements for approximately $18.5 billion (up from $17 billion announced in November 2021) and approximately $3.5 billion in options, including any potential updated COVID-19 vaccine booster candidates. The company is currently in discussions for additional 2022 COVID-19 vaccine contracts.
- Related: Moderna's Authorized COVID-19 Booster Increases Omicron Neutralizing Antibody Levels 37-Fold.
- Additionally, Moderna and Carisma Therapeutics Inc announced a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for cancer.
- Carisma will receive a $45 million upfront cash payment and an investment by Moderna in the form of a $35 million convertible note. Carisma will receive research funding and will receive milestone payments, plus royalties.
- Carisma will be responsible for discovering and optimizing development candidates, while Moderna will lead therapeutics' clinical development and commercialization.
- Moderna has the option to nominate up to twelve targets under the collaboration.
- Price Action: MRNA shares are up 11.8% at $239.10 during the market session on the last check Monday.
